Mapmygenome Lung cancer nicotine dependency test

0
80

May 31, 2014 – HYDERABAD, India — Hyderabad, India, May 31, 2014: 

Mapmygenome India launched a new DNA-based Lung Cancer and Nicotine Dependence test on World No Tobacco Day, May 31, 2014. This test decodes DNA, finds specific changes in the code, and assesses the genetic risk for lung cancer and nicotine dependence. Priced at INR 15,000, this test is recommended to people who have a history of smoking and exposure to environmental tobacco smoke.

Ms. Anu  Acharya, CEO of Mapmygenome, said “Our genetics-based lung cancer and nicotine dependence test is the culmination of requests from several key members of the medical community. This is our way of saying No to tobacco and Yes to oxygen.”

The test uses single nucleotide polymorphism genotyping of proven markers associated with lung cancer in order to study inherited and acquired changes in DNA that contribute to the disease risk. The nicotine dependence markers allow users to understand their nicotine dependence pattern and formulate better smoking cessation plans.

 

 

 

About Mapmygenome

 

Mapmygenome is India’s pioneering Genomics Company with a vision to provide “Better Health for Indians using

 

technology.” They offer personal genomics & diagnostic tests, disease detection kits, brain wellness solutions, and

 

counseling services.

 

They have a range of personal genomics tests that include Genomepatri™ personal genetic profile featuring

 

100+ conditions and traits; Cardiomap™ genetic test for heart disease, diabetes, and other associated lifestyle

 

conditions; Oncomap™ test for cancer; and Gynaecmap™ test for women. These tests assess not only genetic

 

risks for diseases, traits, and conditions, but also responses to several drugs prescribed for treatment. Counseling

 

services such as genetic counseling and nutrition counseling add value to the tests. Along with their partners in

 

diagnostics and healthcare, Mapmygenome paves way for customers to receive the best attention required to

 

mitigate the risk of diseases.

 

Mapmygenome also offers brain wellness solutions in India under the portfolio Mapmybrain™. This

 

includes MyCalmBeat™ to reduce stress, to improve lung function, and to optimize heartbeat. Another innovative

 

product in this range is WebNeuro™ test to screen cognitive strengths and efficiency.

 

Mapmygenome also offers Spoligo TB kit for detecting and typing TB. They also have PCR & sequencing molecular

 

diagnostic tests for β-Thalassemia, Hepatitis B, Hepatitis C, and HIV. More kits and tests will be launched soon

 

other diseases.

 

Their team at Hyderabad comprises biotechnologists, statisticians, geneticists, bioinformaticians, medical writers,

 

and genetic counselors. Their advisory panel has expert scientists and doctors. In order to enhance this innovative

 

brand and to provide value-added services to customers, their highly skilled research team works on cutting-edge

 

technologies in various domains.

 

For more information, visit: Mapmygenome

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here